The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to increase ketone bodies in patients with type 2 diabetes; however, the underlying mechanisms have not been fully elucidated. Here we examined the effect of the SGLT2 inhibitor dapagliflozin (1 mg/kg/day, formulated in a water, PEG40...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallenius, Kristina, Kroon, Tobias, Hagstedt, Therese, Löfgren, Lars, Sörhede-Winzell, Maria, Boucher, Jeremie, Lindén, Daniel, Oakes, Nicholas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953658/
https://www.ncbi.nlm.nih.gov/pubmed/35120993
http://dx.doi.org/10.1016/j.jlr.2022.100176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953658/
https://www.ncbi.nlm.nih.gov/pubmed/35120993
http://dx.doi.org/10.1016/j.jlr.2022.100176

Ejemplares similares